1.Spontaneous Multi-Stage Gluteus Muscular Hemorrhage Following Long-Term Use of Clopidogrel.
Journal of the Korean Neurological Association 2011;29(4):406-406
No abstract available.
Hemorrhage
;
Ticlopidine
2.Strategy for the Treatment of Clopidogrel Low Responsiveness in Diabetes Mellitus and Stent Implantation.
Korean Circulation Journal 2009;39(11):459-461
No abstract available.
Diabetes Mellitus
;
Stents
;
Ticlopidine
3.Hypersexuality Induced by Combination of Bupropion and Clopidogrel.
Meyung Kug KIM ; Yoon Seok HA ; Eung Gyu KIM ; Bong Goo YOO
Journal of the Korean Neurological Association 2011;29(1):57-58
No abstract available.
Bupropion
;
Sexual Behavior
;
Ticlopidine
4.Severe Cholestatic Jaundice and Subsequent Pancytopenia Associated with Ticlopidine.
Hae Seong YOON ; Hyeong Kweon KIM ; Kwang Soo CHA ; Uk Don YOON ; Sam Yong JI ; Joo Ho KIM ; Shin Bae JOO ; Moo Hyun KIM ; Young Dae KIM ; Woo Weon SHIN ; Jong Seong KIM
Korean Circulation Journal 1999;29(11):1259-1263
No abstract available.
Jaundice, Obstructive*
;
Pancytopenia*
;
Ticlopidine*
5.Focused Update of 2009 Korean Clinical Practice Guidelines for the Antiplatelet Therapy in Secondary Prevention of Stroke.
Hyung Min KWON ; Kyung Ho YU ; Keun Sik HONG ; Joung Ho RHA ; Ji Hoe HEO ; Sun Uck KWON ; Chang Wan OH ; Hee Joon BAE ; Byul Chul LEE ; Byung Woo YOON
Journal of the Korean Neurological Association 2010;28(2):81-84
The aim of this update of Korean clinical practice guidelines for stroke is to provide timely evidence-based recommendations on the antiplatelet therapy in secondary prevention of stroke. Evidence-based recommendations are included for the use of antiplatelet agents for noncardioembolic stroke. Changes in the guidelines necessitated by new evidence will be continuously reflected in the new guideline.
Aspirin
;
Platelet Aggregation Inhibitors
;
Secondary Prevention
;
Stroke
;
Ticlopidine
6.Clinical Study on the Antiplatelet Aggregation Effect of Ticlopidine Hydrochloride(Ticlid(R)).
Byung Heui OH ; Myoung Mook LEE ; Young Bae PARK ; Yun Sik CHOI ; Jung Don SEO ; Young Woo LEE
Korean Circulation Journal 1986;16(3):379-387
The antiplatelet aggregation effect of ticlopidine was studied in 22 cases of coronary artery disease(CAD) and 17 cases of control by obseving changes of plarma beta-thromboglobulin(beta-TG) and platelet factor 4(PF-4) before and after administration of ticlopidine 500mmg daily for 2 weeks. 1) Compared with the controls, CAD patients had significantly greater plasm levels of beta-TG(52.6+/-32.7ng/ml. mean +/-SD vs. 91.0+/-52.0, P<0.05) and PF-4(17.5+/-12.8 ng/ml vs. 32.9+/-24.5, P<0.05). 2) In controls, plasma levels of beta-TG and PF-4 didn't change significantly after taking ticlopidine. 3) In CAD patients, plasma levels of beta-TG (91.0+/-52.0ng/ml vs. 53.9+/-20.0, P<0.05) and PF-4(32.9+/-24.5ng/ml vs. 18.8 +/-11.9(P<0.05) decreased significantly after ticlopidine. 4) The side effects were observed in 2 cases such as mild indigestion and urticaria.
Blood Platelets
;
Coronary Vessels
;
Dyspepsia
;
Humans
;
Plasma
;
Ticlopidine*
;
Urticaria
7.Effects of cilostazol treatment on angiographic restenosis after coronary stent placement.
Yun Ho CHU ; Seong Wook PARK ; Cheol Whan LEE ; Myeong Ki HONG ; Jae Joong KIM ; Hyun Sook KIM ; Seong Tae CHO ; Kyeong Suk LEE ; Gi Byoung NAM ; Kee Joon CHOI ; Jae Kwan SONG ; You Ho KIM ; Chong Hun PARK ; Seung Jung PARK
Korean Circulation Journal 2000;30(12):1494-1500
BACKGROUND AND OBJECTIVES: Cilostazol is a potent antiplatelet agent with antiproliferative properties. Few data are available about the effect of cilostazol on post-stenting restenosis. The aim of this study was to evaluate the impact of cilostazol on post-stenting restenosis. MATERIALS AND METHOD: Four hundred and nine patients (494 lesions) scheduled for elective stenting were randomized to receive aspirin plus ticlopidine (group A, n=01, 240 lesions) or aspirin plus cilostazol (group B, n=08, 254 lesions), starting 2 days before stenting. Ticlopidine was given for 1 month and cilostazol for 6 months. Follow-up angiography was performed at 6 months, and clinical evaluation at regular intervals. RESULTS: Baseline characteristics were similar between the two groups. Procedural success rate was 99.6% in group A and 100% in group B. There were no cases of stent thrombosis after stenting. Angiographic follow-up was performed in 380 of the 494 eligible lesions and angiographic restenosis rate was 27% in group A, and 22.9% in group B (p=S). However, diffuse type in-stent restenosis was more common in group A than in group B (54.2% vs 26.8%, respectively, p<0.05). In diabetic patients, angiographic restenosis rate was 50% in group A and 21.7% in group B (p<0.05). Clinical events during the follow-up did not differ between the two groups. CONCLUSION: The combination therapy with aspirin plus cilostazol seems to be an effective antithrombotic regimen with comparable results to aspirin plus ticlopidine, but it does not reduce the overall angiographic restenosis rate after elective coronary stenting.
Angiography
;
Aspirin
;
Follow-Up Studies
;
Humans
;
Stents*
;
Thrombosis
;
Ticlopidine
8.A Case of Stent Thrombosis Occurred at 5 Years after Sirolimus-Eluting Stent Implantation
Chonnam Medical Journal 2011;47(2):124-126
Drug-eluting stents (DES) have reduced the rate of repeated revascularization of target lesions. For this reason, DES are considered to be superior to bare-metal stents in reducing the restenosis rate. However, some problems have been reported after implantation of DES. One of them, stent thrombosis, has arisen as a fatal complication. Dual antiplatelet therapy is recommended for at least 12 months after implantation of DES to prevent stent thrombosis. Here, we report a case of very late stent thrombosis that occurred 1 week after discontinuation of clopidogrel at 5 years (1832 days) after implantation of a sirolimus-eluting stent.
Drug-Eluting Stents
;
Myocardial Infarction
;
Stents
;
Thrombosis
;
Ticlopidine
Result Analysis
Print
Save
E-mail